ALK and non-small cell lung carcinoma: These agents showed significant survival benefits and are now approved for use either as monotherapy or combined with chemotherapy (chemoimmunotherapy) and as a first-line treatment for advanced NSCLC lacking EGFR or ALK driver mutations.